Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies, according to founder and CEO Gary Glick.
https://www.pharmalive.com/wp-content/uploads/2022/10/BioSpaceGaryGlick10-13-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-13 10:00:142022-10-13 13:04:13Odyssey bags $168M to accelerate push to the clinic
